MedTrace Logo

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

NCT06145399 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-05-18

No results posted yet for this study

Summary

The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-FDG PET/CT

Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners

DIAGNOSTIC_TEST

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging

18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.

DRUG

18F-FDHT

18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.

Sponsors & Collaborators

Principal Investigators

  • Maxine Jochelson, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2024-04-29
Completion
2024-04-29
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06145399 on ClinicalTrials.gov